ScandiDos announced today that Delta4 Discover received 510(k) clearance by the U.S. Food and Drug Administration, bringing to market the first device that independently verifies the radiation dose delivered to a patient during radiation treatment.
Delta4 Discover is an in-vivo dosimetry system that provides tools for the measurement of the radiation dose delivered during cancer radiation therapies. By independently verifying all dosage delivery parameters, it greatly increases the quality and overall safety of the most complex and demanding treatment methods. Delta4 Discover verifies Volumetric Modulated Arc Therapy (VMAT) or RapidArc Radiotherapy Technology treatments on tumors and sets the stage for new treatment modalities, including adaptive radiation therapy. For more information visit: http://scandidos.com/home/solutions/at-treatment-qa/deltasup4sup-discover.